Author(s): Ma YJ, He M, Han JA, Yang L, Ji XY
Abstract Share this page
Abstract We aim to study the therapeutic effects of HBsAg-activated DCs and cytokine-induced killer (CIK) cells as adoptive immunotherapy in patients with Chronic Hepatitis B (CHB). Autologous HBsAg-activated DC-CIK cells were infused into patients with CHB to evaluate their effect on HBV-DNA, HBsAg, ALT, etc. The viral load in the treatment group decreased significantly (P < 0.001), while that in the control group did not decrease (P > 0.05). Twenty-one patients (63.6\% efficiency) in the treatment group had a viral response (≥2 log decrease in viral load), while four patients (14.8\% efficiency) from the control group had a viral response. There were significant differences in the viral responses of the two groups (the control group 63.6\% versus the control group 14.8\%, P < 0.001). We concluded that the immunity was enhanced after HBsAg activation in DCs and CIK cells. Reinfusion of autologous HBsAg-activated DC-CIK cells inhibited HBV proliferation in 21 of 33 (63.6\%) patients. © 2013 John Wiley & Sons Ltd.
This article was published in Scand J Immunol
and referenced in Journal of Clinical & Cellular Immunology